These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 11078452)

  • 1. Impaired insulin secretion and increased insulin sensitivity in familial maturity-onset diabetes of the young 4 (insulin promoter factor 1 gene).
    Clocquet AR; Egan JM; Stoffers DA; Muller DC; Wideman L; Chin GA; Clarke WL; Hanks JB; Habener JF; Elahi D
    Diabetes; 2000 Nov; 49(11):1856-64. PubMed ID: 11078452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.
    Byrne MM; Gliem K; Wank U; Arnold R; Katschinski M; Polonsky KS; Göke B
    Diabetes; 1998 Aug; 47(8):1259-65. PubMed ID: 9703326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.
    Kjems LL; Holst JJ; Vølund A; Madsbad S
    Diabetes; 2003 Feb; 52(2):380-6. PubMed ID: 12540611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
    Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC
    Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose utilization and production in patients with maturity-onset diabetes of the young caused by a mutation of the hepatocyte nuclear factor-1alpha gene.
    Surmely JF; Guenat E; Philippe J; Dussoix P; Schneiter P; Temler E; Vaxillaire M; Froguel P; Jéquier E; Tappy L
    Diabetes; 1998 Sep; 47(9):1459-63. PubMed ID: 9726235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.
    Greenbaum CJ; Prigeon RL; D'Alessio DA
    Diabetes; 2002 Apr; 51(4):951-7. PubMed ID: 11916912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.
    Sandhu H; Wiesenthal SR; MacDonald PE; McCall RH; Tchipashvili V; Rashid S; Satkunarajah M; Irwin DM; Shi ZQ; Brubaker PL; Wheeler MB; Vranic M; Efendic S; Giacca A
    Diabetes; 1999 May; 48(5):1045-53. PubMed ID: 10331409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of age and glycemic level on the response of the beta-cell to glucose-dependent insulinotropic polypeptide and peripheral tissue sensitivity to endogenously released insulin.
    Meneilly GS; Ryan AS; Minaker KL; Elahi D
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2925-32. PubMed ID: 9709971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus.
    Shapiro ET; Van Cauter E; Tillil H; Given BD; Hirsch L; Beebe C; Rubenstein AH; Polonsky KS
    J Clin Endocrinol Metab; 1989 Sep; 69(3):571-6. PubMed ID: 2503533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.
    Ahrén B; Larsson H; Holst JJ
    J Clin Endocrinol Metab; 1997 Feb; 82(2):473-8. PubMed ID: 9024239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion.
    Fritsche A; Stefan N; Hardt E; Häring H; Stumvoll M
    Diabetologia; 2000 Jul; 43(7):852-8. PubMed ID: 10952457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
    Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
    Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats.
    Mason TM; Goh T; Tchipashvili V; Sandhu H; Gupta N; Lewis GF; Giacca A
    Diabetes; 1999 Mar; 48(3):524-30. PubMed ID: 10078552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 does not not acutely affect insulin sensitivity in healthy man.
    Orskov L; Holst JJ; Møller J; Orskov C; Møller N; Alberti KG; Schmitz O
    Diabetologia; 1996 Oct; 39(10):1227-32. PubMed ID: 8897012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans.
    Ahrén B; Holst JJ; Mari A
    Diabetes Care; 2003 Oct; 26(10):2860-4. PubMed ID: 14514592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining the effects of hyperglycemia on pancreatic endocrine function in humans: evidence for in vivo glucotoxicity.
    Solomon TP; Knudsen SH; Karstoft K; Winding K; Holst JJ; Pedersen BK
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4682-91. PubMed ID: 23043193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simple empirical assessment of beta-cell function by a constant infusion of glucose test in normal and type 2 (non-insulin-dependent) diabetic subjects.
    Levy JC; Rudenski A; Burnett M; Knight R; Matthews DR; Turner RC
    Diabetologia; 1991 Jul; 34(7):488-99. PubMed ID: 1916054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.